KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardlytics (CDLX) Share-based Compensation (2017 - 2025)

Cardlytics (CDLX) has disclosed Share-based Compensation for 9 consecutive years, with $5.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation fell 36.45% year-over-year to $5.5 million, compared with a TTM value of $28.1 million through Dec 2025, down 30.32%, and an annual FY2025 reading of $28.1 million, down 30.32% over the prior year.
  • Share-based Compensation was $5.5 million for Q4 2025 at Cardlytics, down from $6.4 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $16.8 million in Q3 2021 and bottomed at $5.5 million in Q4 2025.
  • Average Share-based Compensation over 5 years is $10.2 million, with a median of $10.6 million recorded in 2023.
  • Peak annual rise in Share-based Compensation hit 87.43% in 2022, while the deepest fall reached 65.73% in 2022.
  • Year by year, Share-based Compensation stood at $12.8 million in 2021, then decreased by 2.78% to $12.5 million in 2022, then decreased by 11.75% to $11.0 million in 2023, then dropped by 21.33% to $8.7 million in 2024, then tumbled by 36.45% to $5.5 million in 2025.
  • Business Quant data shows Share-based Compensation for CDLX at $5.5 million in Q4 2025, $6.4 million in Q3 2025, and $7.5 million in Q2 2025.